Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.

Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44.

PMID:
10325453
2.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
3.

Donepezil for vascular cognitive impairment.

Malouf R, Birks J.

Cochrane Database Syst Rev. 2004;(1):CD004395. Review.

PMID:
14974068
4.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
5.

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey R.

Cochrane Database Syst Rev. 2003;(3):CD001190. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001190.

PMID:
12917900
6.

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.

Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG.

Int J Geriatr Psychiatry. 2004 Jul;19(7):624-33. Review.

PMID:
15254918
7.

Donepezil for mild and moderate Alzheimer's disease.

Birks J S, Melzer D.

Cochrane Database Syst Rev. 2000;(2):CD001190. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001190.

PMID:
10796620
8.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
9.

Donepezil for mild and moderate Alzheimer's disease.

Birks JS, Melzer D, Beppu H.

Cochrane Database Syst Rev. 2000;(4):CD001190. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD001190.

PMID:
11034704
10.

Defining meaningful change in Alzheimer's disease trials: the donepezil experience.

McLendon BM, Doraiswamy PM.

J Geriatr Psychiatry Neurol. 1999 Spring;12(1):39-48. Review.

PMID:
10447153
11.

Donepezil.

Bryson HM, Benfield P.

Drugs Aging. 1997 Mar;10(3):234-9; discussion 240-1. Review.

PMID:
9108896
12.

Donepezil: in vascular dementia.

Goldsmith DR, Scott LJ.

Drugs Aging. 2003;20(15):1127-36. Review.

PMID:
14651435
13.

Donepezil for dementia in people with Down syndrome.

Mohan M, Carpenter PK, Bennett C.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007178. doi: 10.1002/14651858.CD007178.pub2. Review.

PMID:
19160328
14.

Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.

Prvulovic D, Schneider B.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1039-50. doi: 10.1517/17425255.2014.915028. Epub 2014 Apr 30. Review.

PMID:
24785550
15.

Reviewing the role of donepezil in the treatment of Alzheimer's disease.

Doody RS, Cummings JL, Farlow MR.

Curr Alzheimer Res. 2012 Sep;9(7):773-81. Review.

PMID:
22175653
16.

Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.

Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F.

ScientificWorldJournal. 2013 Oct 29;2013:925702. doi: 10.1155/2013/925702. eCollection 2013. Review.

17.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6. Review.

PMID:
23462265
18.

The safety and tolerability of donepezil in patients with Alzheimer's disease.

Jackson S, Ham RJ, Wilkinson D.

Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:1-8. Review.

19.

Alzheimer's disease: the benefits of early treatment.

Gauthier SG.

Eur J Neurol. 2005 Oct;12 Suppl 3:11-6. Review.

PMID:
16144532
20.

Predicting cognitive decline in Alzheimer's disease: an integrated analysis.

Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R.

Alzheimers Dement. 2010 Nov;6(6):431-9. doi: 10.1016/j.jalz.2010.04.003. Review.

PMID:
21044773
Items per page

Supplemental Content

Write to the Help Desk